C1(C(C2C=CC=CC=2)(C2C=CC=CC=2)[N:8]2[C:12]([C:13]3[CH:18]=[CH:17][CH:16]=[CH:15][C:14]=3[C:19]3[CH:24]=[CH:23][C:22]([CH2:25][N:26]4[N:30]5[N:31]=[C:32]([CH3:34])[N:33]=[C:29]5[C:28]([CH2:35][C:36]5[CH:41]=[CH:40][C:39]([C:42]6[CH:47]=[CH:46][CH:45]=[CH:44][C:43]=6[C:48]6[N:52](C(C7C=CC=CC=7)(C7C=CC=CC=7)C7C=CC=CC=7)[N:51]=[N:50][N:49]=6)=[CH:38][CH:37]=5)=[C:27]4[CH2:72][CH2:73][CH3:74])=[CH:21][CH:20]=3)=[N:11][N:10]=[N:9]2)C=CC=CC=1>C1(C)C=CC=CC=1>[NH:11]1[C:12]([C:13]2[CH:18]=[CH:17][CH:16]=[CH:15][C:14]=2[C:19]2[CH:20]=[CH:21][C:22]([CH2:25][N:26]3[N:30]4[N:31]=[C:32]([CH3:34])[N:33]=[C:29]4[C:28]([CH2:35][C:36]4[CH:41]=[CH:40][C:39]([C:42]5[CH:47]=[CH:46][CH:45]=[CH:44][C:43]=5[C:48]5[NH:49][N:50]=[N:51][N:52]=5)=[CH:38][CH:37]=4)=[C:27]3[CH2:72][CH2:73][CH3:74])=[CH:23][CH:24]=2)=[N:8][N:9]=[N:10]1A 342 mg portion of 5,7-bis[[2'-(N-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methyl]-2-methyl-6-propyl-5H-pyrazolo[1,5-b][1,2,4]triazole (compound 1a) was treated in the same manner as described in Example 12, the resulting residue was mixed with toluene and heated under reflux and then the solution was cooled spontaneously to collect the thus formed precipitate by filtration, thereby giving 182 mg of 5,7-bis[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-2-methyl- 6-propyl-5H-pyrazolo[1,5-b][1,2,4]triazole in the form of colorless amorphous solid.
読み込み中…